Coccidioidomycosis - Pipeline Insight, 2024

This “Coccidioidomycosis - Pipeline Insight, 2024,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Coccidioidomycosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Coccidioidomycosis Understanding

Coccidioidomycosis: Overview

Coccidioidomycosis is caused by Coccidioides immitis, a soil fungus native to the San Joaquin Valley of California, and by C posadasii, which is endemic to certain arid-to-semiarid areas of the southwestern United States, northern portions of Mexico, and scattered areas in Central America and South America. Although genetically distinct, the 2 species are morphologically identical. Coccidioidomycosis is typically transmitted by inhalation of airborne spores of C immitis or C posadasii. Infection occurs in endemic areas and is most commonly acquired in the summer or the late fall during outdoor activities. In most patients with coccidioidal infection, the primary infection is in the lungs. In 60-65% of cases, this infection is asymptomatic. Diagnosis requires isolation of the organism in culture, identification on histologic specimens, or serologic testing (see Workup). Most patients infected with Coccidioides are asymptomatic or have self-limited symptoms and require only supportive care. Symptomatic patients usually come to medical attention because of respiratory tract or systemic manifestations. Management in symptomatic patients varies with the clinical syndrome

Coccidioidomycosis - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Coccidioidomycosis pipeline landscape is provided which includes the disease overview and Coccidioidomycosis treatment guidelines. The assessment part of the report embraces, in depth Coccidioidomycosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Coccidioidomycosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Coccidioidomycosis.
• In the coming years, the Coccidioidomycosis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence Coccidioidomycosis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Coccidioidomycosis treatment market. Several potential therapies for Coccidioidomycosis are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Coccidioidomycosis market size in the coming years.
• This in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Coccidioidomycosis) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Coccidioidomycosis Emerging Drugs Chapters

This segment of the Coccidioidomycosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Coccidioidomycosis Emerging Drugs

Ibrexafungerp: SCYNEXISIbrexafungerp (formerly SCY-078) is the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids. It has shown activity against Aspergillus and Candida, including against multidrug-resistant (MDR) species Candida auris as well as Pneumocystis. Ibrexafungerp combines the well-established activity of glucan synthase inhibitors with the flexibility of oral and IV formulations, offering a broad use across different settings (in-patient and out-patient).

VT-1598: Mycovia PharmaceuticalsMycovia is currently evaluating VT-1598, an oral antifungal, in Phase 1 clinical trials, for the treatment of serious fungal pathogens that pose a growing global threat due to underlying multidrug resistance. VT-1598 has QIDP designation, Fast Track status, and orphan designation for Valley fever (coccidioides); cryptococcal meningitis is eligible for FDA’s priority review voucher program.

Coccidioidomycosis: Therapeutic Assessment

This segment of the report provides insights about the different Coccidioidomycosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Coccidioidomycosis

There are approx. 3+ key companies which are developing the therapies for Coccidioidomycosis. The companies which have their Coccidioidomycosis drug candidates in the most advanced stage, i.e. phase III include, SCYNEXIS.

Phases

This report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Coccidioidomycosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Coccidioidomycosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Coccidioidomycosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Coccidioidomycosis drugs.

Coccidioidomycosis Report Insights

• Coccidioidomycosis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Coccidioidomycosis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Coccidioidomycosis drugs?
• How many Coccidioidomycosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Coccidioidomycosis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Coccidioidomycosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Coccidioidomycosis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• SCYNEXIS
• Mycovia Pharmaceuticals
• Amplyx Pharmaceuticals
• F2G

Key Products

• Ibrexafungerp
• VT-1598
• Fosmanogepix
• F-901318